Alligator Bioscience´s ADC-1004 for treatment of ischemia reperfusion injury reduced myocardial infarct size
Alligator Bioscience announced positive results from its drug candidate ADC-1004 in a closed-chest porcine model of acute myocardial infarction (AMI). ADC-1004 was found to significantly reduce infarct size, which in the clinical situation is expected to reduce mortality, incidence of heart failure and incidence of malignant arrhythmias. In addition, preliminary studies of ADC-1004 in two other I/R injury models, a porcine transplantation model and a rat stroke model, showed promising results supporting the hypothesis of ADC-1004's role in I/R injury.
Bengt Larsson, Chief Medical Officer at Alligator Bioscience, says "we believe ADC-1004 has the potential to become a standard add-on treatment in any situation where I/R injury is a risk, including AMI treated with PCI". Gun-Britt Fransson, Chief Executive Officer of Alligator Bioscience comments "We are of course encouraged by the positive results obtained in the animal models. We realize that the potential of ADC-1004 to reduce mortality in some of the most frequent death causing diseases, and to give a better life of millions of patients, is significant. We look forward to develop this candidate in collaboration with a partner with expertise in diseases where I/R injury is crucial, such as AMI, stroke, and transplantation."
Other news from the department research and development
